Larry J. Jolivette completed his doctoral training in pharmacology at the University of Rochester in 2001 under the direction of Dr. M. W. ‘Drag’ Anders. Dr. Jolivette then joined the Department of Preclinical Pharmacokinetics within the Cardiovascular and Urogenital Center of Excellence for Drug Discovery at GlaxoSmithKline where he led in vitro and in silico drug metabolism efforts. His areas of responsibility eventually grew to include the CVU CEDD’s preclinical pharmacokinetics and bioanalytical groups. Currently, Dr. Jolivette is a department head and a member of the leadership team for the Heart Failure Discovery Performance Unit at GSK with oversight responsibility for nonclinical developability assessment (DMPK, CMC, pharmaceutics, and safety assessment) of potential new heart failure therapeutics.
Appearing:
Day Two, Thursday 21 October 2010
11am
Challenges and Solutions to Safety Testing of Drug Metabolites
Impact of safety testing of drug metabolites on early clinical development planning
Current practices for assessment of drug metabolites in nonclinical and early clinical development
Considerations for the integration of drug metabolism and safety assessment data with early nonclinical and clinical development decision making
Nadine Cohen
Mitchell B. Friedman
Malcolm Mitchell
Dr Russell Weiner
